-
-
-
-
-
-
-
After-hours movers: UiPath, SentinelOne, Under Armour, and more
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
-
-
-
-
-
-
-
Citi Starts Coherus Biosciences (CHRS) at Buy, 'Come for the Biosimilars, Stay for the I/O Pipeline'
-
-
-
-
-
-
-
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
-
-
-
-
-
-
-
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
-
-
-
-
-
-
-
Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development
-
-
-
-
-
-
-
Unusual 11 Mid-Day Movers 5/17: (MGT) (TISA) (CYTX) Higher; (FRAN) (AEGR) (VSR) Lower
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

